Inside the Structural Reforms That Made IU Indianapolis a Translational Overachiever
How a resource-constrained university built a top-15 translation engine — and what other institutions can learn from it.
47
The University of Texas M. D. Anderson Cancer Center ranks 47th among universities in the Cure Innovation Index and is located in Houston, Texas. The center places eighth in Research Capabilities, reflecting strong scientific output and investigative infrastructure. Market Translation falls above average for universities in this category, while Entrepreneurial Readiness sits near the field's midpoint. M. D. Anderson supports physician-scientist training through an MSTP program and provides an incubator for emerging ventures. Its profile leans toward discovery, consistent with the institution's long-standing focus on cancer biology and translational oncology research.
University of Texas M. D. Anderson Cancer Center ranked above average for Research Capabilities, a measure of the foundational infrastructure and resources that enable an institution to conduct high-quality, innovative science. Out of the factors in this category, University of Texas M. D. Anderson Cancer Center fared best in Funding Support.
Learn MoreUniversity of Texas M. D. Anderson Cancer Center ranked below average for Entrepreneurial Readiness, a measure of whether the institution has built a supportive ecosystem for entrepreneurship and whether faculty are engaged in and incentivized toward commercial activity. Out of the factors in this category, University of Texas M. D. Anderson Cancer Center fared best in Ecosystem Support.
Learn MoreUniversity of Texas M. D. Anderson Cancer Center ranked above average for Market Translation, a measure of how effectively a research institution moves scientific discovery out of the lab and into real-world clinical and commercial applications. Out of the factors in this category, University of Texas M. D. Anderson Cancer Center fared best in Industry Connections.
Learn More
From a pool of more than 6,000 institutions, the top 303 were ranked using two dozen indicators — from scientific foundation and lab infrastructure to patents, products, and partnerships — drawn from more than a dozen federal and commercial databases, an original audit of all institutions, and surveys of more than 3,300+ scientists, industry leaders, and biomedical experts.
Innovation isn't a single moment — it's an entire ecosystem. The Index evaluates institutions across two dozen indicators, grouped in three core domains that reveal the full picture of what it takes to turn groundbreaking science into real-world impact.
How a resource-constrained university built a top-15 translation engine — and what other institutions can learn from it.
With 27 institutions ranked among the country’s top biomedical innovators, New York’s research cluster spans the entire state, and outperforms nearly every other in the country.

As NIH funding shrinks and industry pulls back from early-stage science, universities are rethinking how discoveries move from the lab to the market.
The Bayh-Dole Act turned federally funded research into a commercialization pipeline that built American biotech. Forty-five years later, that pipeline faces a new set of political and financial pressures that could reshape how it works.